Safety of Intravenous Lidocaine Infusions

This study has been completed.
University of Western Ontario, Canada
Information provided by:
Lawson Health Research Institute Identifier:
First received: March 22, 2010
Last updated: March 23, 2010
Last verified: March 2010
The purpose of this study is to prospectively determine the side effects profile in adults with neuropathic pain receiving intravenous infusions of lidocaine 5 mg per kg of lean body weight, infused over 45 minutes.

Neuropathic Pain

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Safety of Intravenous Lidocaine Infusions for Chronic Neuropathic Pain

Resource links provided by NLM:

Further study details as provided by Lawson Health Research Institute:

Enrollment: 70
Study Start Date: June 2009
Study Completion Date: January 2010
Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)

Adults >18 yrs , attending St Joseph's Health Care Pain Clinic with a diagnosis of chronic neuropathic pain who are being treated with an lidocaine infusion of 5 mg/kg over 45 minutes

Consecutive patients from two time periods:

  1. June 15 to August 21, 2009
  2. October 15-Dec 22,2009

Detailed Description:

Eligibility Criteria:

Adults > 18 yrs with chronic central or peripheral neuropathic pain at the St Joseph's Health Care Pain Clinic between June and December 2009.

Outcome measures: All side effects spontaneously reported. Sedation, nausea, dizziness by Visual Analog Score Q 15 minutes; hemodynamic data q 5 minutes during and after infusion for 30 minutes.

Daily diary of side effects and Visual Analogue score of Pain for 7 days post-infusion.


Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Adult outpatients attending St Joseph's Chronic Pain Clinic in one of two time periods who have been diagnosed with chronic neuropathic pain by clinical history and examination and are scheduled to receive a lidocaine infusion for pain management

Inclusion Criteria:

  • Adult outpatients > 18 years < 80 years diagnosed with chronic neuropathic pain

Exclusion Criteria:

  • Unable to provide informed consent
  • Unable to speak and understand English
  • Liver, kidney, or cardiac failure
  • Allergy to Lidocaine
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01091935

Canada, Ontario
St Joseph's Health Care
London, Ontario, Canada, N6A 4V2
Sponsors and Collaborators
Lawson Health Research Institute
University of Western Ontario, Canada
Principal Investigator: Patricia K Morley-Forster, MD, FRCPC Associate Professor,Dept of Anesthesia and Perioperative Medicine,University of Western Ontario, Lawson Health Research Institute
Principal Investigator: Patricia K Morley-Forster, MD, FRCPC Associate Professor, University of Western Ontario, Lawson Health Research Institute
  More Information

Responsible Party: Patricia Morley-Forster, St Joseph's Health Care Identifier: NCT01091935     History of Changes
Other Study ID Numbers: R-08-341  15240E 
Study First Received: March 22, 2010
Last Updated: March 23, 2010
Health Authority: Canada: Ethics Review Committee

Keywords provided by Lawson Health Research Institute:
Lidocaine,Intravenous Infusions,Neuropathic Pain,Side Effects

Additional relevant MeSH terms:
Nervous System Diseases
Neurologic Manifestations
Neuromuscular Diseases
Peripheral Nervous System Diseases
Signs and Symptoms
Anesthetics, Local
Anti-Arrhythmia Agents
Cardiovascular Agents
Central Nervous System Agents
Central Nervous System Depressants
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Sodium Channel Blockers
Therapeutic Uses
Voltage-Gated Sodium Channel Blockers processed this record on May 02, 2016